An anti-CTLA-4 monoclonal antibody (ipilimumab) and a BRAF inhibitor (vemurafenib) were approved in 2011 by FDA to treat advanced melanoma, which herald a new era of targeted therapeutics for melanoma [8], [9]. The gene discussed is BRAF; the disease is melanoma.